Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF versus rhG-CSF for prevention of severe chemotherapy-induced neutropenia in gynecologic malignancies
ChiCTR1900023174Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegfilgrastim and filgrastim in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Incidence and duration of grade III/IV neutropenia and febrile neutropenia. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR1900023174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023174.